The last two decades have witnessed major breakthroughs in the development of targeted therapy for patients with metastatic colorectal cancer (mcrc), an achievement which stems largely from advances in translational research. Patients with advanced or metastatic colorectal cancer ((m)crc) have limited effective treatment options resulting in high mortality rates Most tyrosine kinase inhibitors (tkis) have failed in clinical trials for metastatic colorectal cancer (mcrc)
Maxy May : EliteFemale
New trial results reveal zanzalintinib and atezolizumab significantly enhance survival in metastatic colorectal cancer, marking a breakthrough in treatment options
Patients with heavily pretreated microsatellite stable metastatic colorectal cancer (crc) had survival benefits after using combinations based in immune checkpoint inhibitors.
